Studies have found that the IL-6/AKT signaling pathway promotes Mcl-1 expression in cholangiocarcinoma, which in turn mediates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) resistance in cholangiocarcinoma patients [36]. The gene discussed is MCL1; the disease is cholangiocarcinoma.